Factors influencing behavioral cough suppression therapy in children with nonspecific chronic cough

Robert Brinton Fujiki1, Miranda L Wright2,3, Amanda E Fujiki4

  • 1Department of Surgery, University of Wisconsin - Madison, Madison, Wisconsin, USA.

Pediatric Pulmonology
|September 22, 2023
PubMed

Insights

Behavioral cough suppression therapy (BCST) effectively treats chronic cough in children, often resolving symptoms in just a few sessions. This low-risk therapy shows promising results for pediatric patients with nonspecific cough.

Area of Science:

  • Pediatric Otolaryngology
  • Speech-Language Pathology
  • Behavioral Therapy

Background:

  • Chronic nonspecific cough, also known as tic cough, is common in children.
  • Behavioral cough suppression therapy (BCST) is a frequent treatment, but its effectiveness and duration are not well-documented.
  • This study aimed to evaluate pediatric BCST outcomes and identify predictive factors.

Purpose of the Study:

  • To determine the efficacy of BCST in improving chronic cough in children.
  • To identify factors that predict the number of BCST sessions required.
  • To characterize cough features and associated comorbidities in pediatric patients.

Main Methods:

  • Retrospective observational cohort study.
  • Data extracted from electronic medical records of 151 children treated at a pediatric otolaryngology clinic.
  • Included cough characteristics, medical history, BCST details, and outcomes.

Main Results:

  • Most coughs were dry, often preceded by a tickle, and present for an average of 19 months.
  • High rates of comorbidities observed: reflux (62.3%), General Anxiety Disorder, asthma (22.1%), and disordered sleep breathing (19.2%).
  • BCST reduced cough in 92.5% of patients within an average of 1.7 sessions; behavioral health diagnoses and ILS symptoms predicted more sessions.

Conclusions:

  • BCST appears to be a low-risk and effective treatment for pediatric chronic nonspecific cough.
  • Further investigation with randomized clinical trials is warranted.
  • Understanding comorbidities and cough characteristics can inform treatment approaches.
Abstract

Related Concept Videos

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
318
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.6K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
236
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.3K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
474
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
279